The global antibody market size is estimated to be worth around 266.83 billion in 2024. The total market value of the antibodies sector is anticipated to increase at a CAGR of 8.1% from 2024 to 2034. Furthermore, it is anticipated that the market for antibodies will reach USD 581.42 billion by 2034. The total market growth of the antibodies sector represented in absolute dollars is USD 315 billion.
Report Attribute | Details |
---|---|
Antibody Market Size (2024) | USD 266.83 billion |
Market Anticipated Forecast Value (2034) | USD 581.42 billion |
Market Projected Growth Rate (2024 to 2034) | 8.1% CAGR |
The global antibody market was valued at USD 131.47 billion in 2019. The market overview of antibody drugs progressed at an annual rate of 12.5% between 2019 and 2023. The overall market value was about USD 236.86 billion by 2023.
Attributes | Details |
---|---|
Antibody Market Value (2019) | USD 131.47 billion |
Market Revenue (2023) | USD 236.86 billion |
Market Historical Growth Rate (CAGR 2019 to 2023) | 12.5% CAGR |
Research and Development Activities Impact Antibodies Sales Outlook
A surge in research and development activities among pharmaceutical market leaders to develop economical and effective antibodies is driving growth opportunities for diagnostic specialty antibody suppliers.
In February 2021, Abingdon Health collaborated with Abcam to explore opportunities for their service and portfolio expansion which includes Abcam's reagent portfolio and Abingdon Health's rapid test contract development and manufacturing services.
Rising cases of multiple sclerosis and Parkinson's disease among the older population is a key factor fueling the demand for antibodies. There is an urgency to develop personalized and cheap medicines, advanced therapeutics, advanced genetic engineering technology, and novel and effective treatments in middle-income countries.
In 2021, Berkeley Lights, a digital cell biology company, joined hands with Genovac, an antibody discovery company, to readily access the right antibodies in the shortest amount of time with the help of modern technology.
Increasing Production of Bio-similar Antibodies is Driving Demand
Biosimilar antibodies are experiencing heavy demand as they are inexpensive in comparison with human monoclonal antibodies, and they have very few side effects. In 2020, Johnson and Johnson reported USD 3.75 Billion achieved through the sales of Remicade. According to Pfizer, Inflectra, the biosimilar competitor of Remicade, generated USD 659 million in 2020.
USA Food and Drug Administration (FDA) approved a biosimilar of Remicade called Avsola in December 2019 and is now eligible for producing biologics products all over the world. Increasing demand for biosimilar antibodies in the treatment of rheumatoid arthritis, along with a high patient acceptance rate, is anticipated to boost the market growth for antibodies.
One of the leaders in prescription medicines, Pfizer, received EU approval for biosimilar antibody therapeutics Amsparity for Crohn’s disease, psoriasis, and psoriatic arthritis in February 2020. Elevated new drug approval rates and products in clinical trials in pharmaceutical companies are anticipated to further drive the market in the upcoming years.
The table below mentions the countries that are expected to witness higher growth opportunities in this market.
Regional Market Comparison | CAGR (2024 to 2034) |
---|---|
United States | 9.6% |
Germany | 9.4% |
United Kingdom | 10.1% |
India | 9.5% |
China | 6.5% |
The United States therapeutic antibodies market is poised to advance at a rate of 10.1% per year till 2034.
Consumption of antibody products in the United Kingdom is projected to rise at a rate of 10.1% during the forecast years.
The antibodies industry in China is projected to thrive at a CAGR of 5.8% through the projected years.
Sales of antibodies in Germany are anticipated to increase at a rate of 9.4% from 2024 to 2034.
Demand for antibodies in India is expected to rise at a rate of 9.5% per year between 2024 and 2034.
Based on product type, the monoclonal antibodies market segment is estimated to account for 95% of the market share in 2024.
Attributes | Details |
---|---|
Top Product Type or Segment | Monoclonal Antibodies |
Total Market Share in 2024 | 95% |
Based on disease indication, the use of antibodies for treating cancer is expected to account for 57% of the total sales in 2024.
Attributes | Details |
---|---|
Top Disease Indication Type or Segment | Cancer |
Total Market Share in 2024 | 57% |
Leading market players are working towards developing new antibodies to remain competitive in the present market. They are also researching to create long-acting antibody drugs to reduce healthcare costs and attract chronic patients.
In order to gain a competitive edge in the antibody testing market, key players are developing oral and noninvasive treatments using antibodies to treat chronic ailments. Strategic mergers and acquisitions for portfolio expansion are in the cards as well.
Future market players should concentrate on acquiring additional money through financing rounds to broaden their research and company scope. New businesses are looking into how to leverage cutting-edge technologies to streamline the creation of therapeutic antibodies, including nanobodies and monoclonal antibodies.
Recent Developments in the Global Antibody Market
On June 11, 2021, Novartis published its new Phase II data of an investigational oral treatment iptacopan, developed for treating paroxysmal nocturnal hemoglobinuria (PNH). The study indicated that during 12 weeks of iptacopan monotherapy treatment, no unexpected safety issues were reported which led to rapid and durable transfusion-free improvement of hemoglobin levels in the majority of patients.
In August 2020, Johnson & Johnson entered into a final agreement to acquire Momenta Pharmaceuticals Inc. for around USD 6.5 Billion. Momenta Pharmaceuticals Inc. is a market leader in developing novel therapies for immune-mediated diseases.
The acquisition may allow the Janssen Pharmaceutical Companies of Johnson & Johnson to expand its product portfolio in immune-mediated diseases while driving growth opportunities through expansion into autoantibody-driven disease.
Leading pharmaceutical company Sanofi announced in March 2022 that it will collaborate with IGM Biosciences to research, produce, and market six novel immunoglobulin M antibody agonists. Sanofi has agreed to approximately USD 6 billion in possible milestone payments through this agreement.
Attribute | Details |
---|---|
Estimated Market Size (2024) | USD 266.83 billion |
Projected Market Size (2034) | USD 581.42 billion |
Anticipated Growth Rate (2024 to 2034) | 8.1% |
Forecast Period | 2024 to 2034 |
Historical Data Available for | 2019 to 2023 |
Market Analysis | USD million or billion for Value and Units for Volume |
Key Regions Covered | North America; Latin America; Europe; Middle East & Africa (MEA); East Asia; South Asia and Oceania |
Key Countries Covered | United States, Canada, Brazil, Mexico, Germany, Spain, Italy, France, United Kingdom, Russia, China, India, Australia & New Zealand, GCC Countries, and South Africa |
Key Segments Covered | By Product Type, By Disease Indication, By End Use Verticals, and By Region |
Key Companies Profiled | Novartis AG; F. Hoffmann-La Roche AG; Johnson & Johnson; Takeda Pharmaceutical Company Limited; Amgen Inc. |
Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
Customization & Pricing | Available upon Request |
Table 1: Global Market Value (US$ Million) Forecast by Region, 2019 to 2034
Table 2: Global Market Value (US$ Million) Forecast by Disease Indication, 2019 to 2034
Table 3: Global Market Value (US$ Million) Forecast by Product Type, 2019 to 2034
Table 4: Global Market Value (US$ Million) Forecast by End User, 2019 to 2034
Table 5: North America Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 6: North America Market Value (US$ Million) Forecast by Disease Indication, 2019 to 2034
Table 7: North America Market Value (US$ Million) Forecast by Product Type, 2019 to 2034
Table 8: North America Market Value (US$ Million) Forecast by End User, 2019 to 2034
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 10: Latin America Market Value (US$ Million) Forecast by Disease Indication, 2019 to 2034
Table 11: Latin America Market Value (US$ Million) Forecast by Product Type, 2019 to 2034
Table 12: Latin America Market Value (US$ Million) Forecast by End User, 2019 to 2034
Table 13: Western Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 14: Western Europe Market Value (US$ Million) Forecast by Disease Indication, 2019 to 2034
Table 15: Western Europe Market Value (US$ Million) Forecast by Product Type, 2019 to 2034
Table 16: Western Europe Market Value (US$ Million) Forecast by End User, 2019 to 2034
Table 17: Eastern Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 18: Eastern Europe Market Value (US$ Million) Forecast by Disease Indication, 2019 to 2034
Table 19: Eastern Europe Market Value (US$ Million) Forecast by Product Type, 2019 to 2034
Table 20: Eastern Europe Market Value (US$ Million) Forecast by End User, 2019 to 2034
Table 21: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 22: South Asia and Pacific Market Value (US$ Million) Forecast by Disease Indication, 2019 to 2034
Table 23: South Asia and Pacific Market Value (US$ Million) Forecast by Product Type, 2019 to 2034
Table 24: South Asia and Pacific Market Value (US$ Million) Forecast by End User, 2019 to 2034
Table 25: East Asia Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 26: East Asia Market Value (US$ Million) Forecast by Disease Indication, 2019 to 2034
Table 27: East Asia Market Value (US$ Million) Forecast by Product Type, 2019 to 2034
Table 28: East Asia Market Value (US$ Million) Forecast by End User, 2019 to 2034
Table 29: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 30: Middle East and Africa Market Value (US$ Million) Forecast by Disease Indication, 2019 to 2034
Table 31: Middle East and Africa Market Value (US$ Million) Forecast by Product Type, 2019 to 2034
Table 32: Middle East and Africa Market Value (US$ Million) Forecast by End User, 2019 to 2034
Figure 1: Global Market Value (US$ Million) by Disease Indication, 2024 to 2034
Figure 2: Global Market Value (US$ Million) by Product Type, 2024 to 2034
Figure 3: Global Market Value (US$ Million) by End User, 2024 to 2034
Figure 4: Global Market Value (US$ Million) by Region, 2024 to 2034
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2019 to 2034
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2024 to 2034
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2024 to 2034
Figure 8: Global Market Value (US$ Million) Analysis by Disease Indication, 2019 to 2034
Figure 9: Global Market Value Share (%) and BPS Analysis by Disease Indication, 2024 to 2034
Figure 10: Global Market Y-o-Y Growth (%) Projections by Disease Indication, 2024 to 2034
Figure 11: Global Market Value (US$ Million) Analysis by Product Type, 2019 to 2034
Figure 12: Global Market Value Share (%) and BPS Analysis by Product Type, 2024 to 2034
Figure 13: Global Market Y-o-Y Growth (%) Projections by Product Type, 2024 to 2034
Figure 14: Global Market Value (US$ Million) Analysis by End User, 2019 to 2034
Figure 15: Global Market Value Share (%) and BPS Analysis by End User, 2024 to 2034
Figure 16: Global Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034
Figure 17: Global Market Attractiveness by Disease Indication, 2024 to 2034
Figure 18: Global Market Attractiveness by Product Type, 2024 to 2034
Figure 19: Global Market Attractiveness by End User, 2024 to 2034
Figure 20: Global Market Attractiveness by Region, 2024 to 2034
Figure 21: North America Market Value (US$ Million) by Disease Indication, 2024 to 2034
Figure 22: North America Market Value (US$ Million) by Product Type, 2024 to 2034
Figure 23: North America Market Value (US$ Million) by End User, 2024 to 2034
Figure 24: North America Market Value (US$ Million) by Country, 2024 to 2034
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 28: North America Market Value (US$ Million) Analysis by Disease Indication, 2019 to 2034
Figure 29: North America Market Value Share (%) and BPS Analysis by Disease Indication, 2024 to 2034
Figure 30: North America Market Y-o-Y Growth (%) Projections by Disease Indication, 2024 to 2034
Figure 31: North America Market Value (US$ Million) Analysis by Product Type, 2019 to 2034
Figure 32: North America Market Value Share (%) and BPS Analysis by Product Type, 2024 to 2034
Figure 33: North America Market Y-o-Y Growth (%) Projections by Product Type, 2024 to 2034
Figure 34: North America Market Value (US$ Million) Analysis by End User, 2019 to 2034
Figure 35: North America Market Value Share (%) and BPS Analysis by End User, 2024 to 2034
Figure 36: North America Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034
Figure 37: North America Market Attractiveness by Disease Indication, 2024 to 2034
Figure 38: North America Market Attractiveness by Product Type, 2024 to 2034
Figure 39: North America Market Attractiveness by End User, 2024 to 2034
Figure 40: North America Market Attractiveness by Country, 2024 to 2034
Figure 41: Latin America Market Value (US$ Million) by Disease Indication, 2024 to 2034
Figure 42: Latin America Market Value (US$ Million) by Product Type, 2024 to 2034
Figure 43: Latin America Market Value (US$ Million) by End User, 2024 to 2034
Figure 44: Latin America Market Value (US$ Million) by Country, 2024 to 2034
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 48: Latin America Market Value (US$ Million) Analysis by Disease Indication, 2019 to 2034
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Disease Indication, 2024 to 2034
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Disease Indication, 2024 to 2034
Figure 51: Latin America Market Value (US$ Million) Analysis by Product Type, 2019 to 2034
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Product Type, 2024 to 2034
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Product Type, 2024 to 2034
Figure 54: Latin America Market Value (US$ Million) Analysis by End User, 2019 to 2034
Figure 55: Latin America Market Value Share (%) and BPS Analysis by End User, 2024 to 2034
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034
Figure 57: Latin America Market Attractiveness by Disease Indication, 2024 to 2034
Figure 58: Latin America Market Attractiveness by Product Type, 2024 to 2034
Figure 59: Latin America Market Attractiveness by End User, 2024 to 2034
Figure 60: Latin America Market Attractiveness by Country, 2024 to 2034
Figure 61: Western Europe Market Value (US$ Million) by Disease Indication, 2024 to 2034
Figure 62: Western Europe Market Value (US$ Million) by Product Type, 2024 to 2034
Figure 63: Western Europe Market Value (US$ Million) by End User, 2024 to 2034
Figure 64: Western Europe Market Value (US$ Million) by Country, 2024 to 2034
Figure 65: Western Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 66: Western Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 67: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 68: Western Europe Market Value (US$ Million) Analysis by Disease Indication, 2019 to 2034
Figure 69: Western Europe Market Value Share (%) and BPS Analysis by Disease Indication, 2024 to 2034
Figure 70: Western Europe Market Y-o-Y Growth (%) Projections by Disease Indication, 2024 to 2034
Figure 71: Western Europe Market Value (US$ Million) Analysis by Product Type, 2019 to 2034
Figure 72: Western Europe Market Value Share (%) and BPS Analysis by Product Type, 2024 to 2034
Figure 73: Western Europe Market Y-o-Y Growth (%) Projections by Product Type, 2024 to 2034
Figure 74: Western Europe Market Value (US$ Million) Analysis by End User, 2019 to 2034
Figure 75: Western Europe Market Value Share (%) and BPS Analysis by End User, 2024 to 2034
Figure 76: Western Europe Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034
Figure 77: Western Europe Market Attractiveness by Disease Indication, 2024 to 2034
Figure 78: Western Europe Market Attractiveness by Product Type, 2024 to 2034
Figure 79: Western Europe Market Attractiveness by End User, 2024 to 2034
Figure 80: Western Europe Market Attractiveness by Country, 2024 to 2034
Figure 81: Eastern Europe Market Value (US$ Million) by Disease Indication, 2024 to 2034
Figure 82: Eastern Europe Market Value (US$ Million) by Product Type, 2024 to 2034
Figure 83: Eastern Europe Market Value (US$ Million) by End User, 2024 to 2034
Figure 84: Eastern Europe Market Value (US$ Million) by Country, 2024 to 2034
Figure 85: Eastern Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 86: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 87: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 88: Eastern Europe Market Value (US$ Million) Analysis by Disease Indication, 2019 to 2034
Figure 89: Eastern Europe Market Value Share (%) and BPS Analysis by Disease Indication, 2024 to 2034
Figure 90: Eastern Europe Market Y-o-Y Growth (%) Projections by Disease Indication, 2024 to 2034
Figure 91: Eastern Europe Market Value (US$ Million) Analysis by Product Type, 2019 to 2034
Figure 92: Eastern Europe Market Value Share (%) and BPS Analysis by Product Type, 2024 to 2034
Figure 93: Eastern Europe Market Y-o-Y Growth (%) Projections by Product Type, 2024 to 2034
Figure 94: Eastern Europe Market Value (US$ Million) Analysis by End User, 2019 to 2034
Figure 95: Eastern Europe Market Value Share (%) and BPS Analysis by End User, 2024 to 2034
Figure 96: Eastern Europe Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034
Figure 97: Eastern Europe Market Attractiveness by Disease Indication, 2024 to 2034
Figure 98: Eastern Europe Market Attractiveness by Product Type, 2024 to 2034
Figure 99: Eastern Europe Market Attractiveness by End User, 2024 to 2034
Figure 100: Eastern Europe Market Attractiveness by Country, 2024 to 2034
Figure 101: South Asia and Pacific Market Value (US$ Million) by Disease Indication, 2024 to 2034
Figure 102: South Asia and Pacific Market Value (US$ Million) by Product Type, 2024 to 2034
Figure 103: South Asia and Pacific Market Value (US$ Million) by End User, 2024 to 2034
Figure 104: South Asia and Pacific Market Value (US$ Million) by Country, 2024 to 2034
Figure 105: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 106: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 107: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 108: South Asia and Pacific Market Value (US$ Million) Analysis by Disease Indication, 2019 to 2034
Figure 109: South Asia and Pacific Market Value Share (%) and BPS Analysis by Disease Indication, 2024 to 2034
Figure 110: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Disease Indication, 2024 to 2034
Figure 111: South Asia and Pacific Market Value (US$ Million) Analysis by Product Type, 2019 to 2034
Figure 112: South Asia and Pacific Market Value Share (%) and BPS Analysis by Product Type, 2024 to 2034
Figure 113: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Product Type, 2024 to 2034
Figure 114: South Asia and Pacific Market Value (US$ Million) Analysis by End User, 2019 to 2034
Figure 115: South Asia and Pacific Market Value Share (%) and BPS Analysis by End User, 2024 to 2034
Figure 116: South Asia and Pacific Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034
Figure 117: South Asia and Pacific Market Attractiveness by Disease Indication, 2024 to 2034
Figure 118: South Asia and Pacific Market Attractiveness by Product Type, 2024 to 2034
Figure 119: South Asia and Pacific Market Attractiveness by End User, 2024 to 2034
Figure 120: South Asia and Pacific Market Attractiveness by Country, 2024 to 2034
Figure 121: East Asia Market Value (US$ Million) by Disease Indication, 2024 to 2034
Figure 122: East Asia Market Value (US$ Million) by Product Type, 2024 to 2034
Figure 123: East Asia Market Value (US$ Million) by End User, 2024 to 2034
Figure 124: East Asia Market Value (US$ Million) by Country, 2024 to 2034
Figure 125: East Asia Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 126: East Asia Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 127: East Asia Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 128: East Asia Market Value (US$ Million) Analysis by Disease Indication, 2019 to 2034
Figure 129: East Asia Market Value Share (%) and BPS Analysis by Disease Indication, 2024 to 2034
Figure 130: East Asia Market Y-o-Y Growth (%) Projections by Disease Indication, 2024 to 2034
Figure 131: East Asia Market Value (US$ Million) Analysis by Product Type, 2019 to 2034
Figure 132: East Asia Market Value Share (%) and BPS Analysis by Product Type, 2024 to 2034
Figure 133: East Asia Market Y-o-Y Growth (%) Projections by Product Type, 2024 to 2034
Figure 134: East Asia Market Value (US$ Million) Analysis by End User, 2019 to 2034
Figure 135: East Asia Market Value Share (%) and BPS Analysis by End User, 2024 to 2034
Figure 136: East Asia Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034
Figure 137: East Asia Market Attractiveness by Disease Indication, 2024 to 2034
Figure 138: East Asia Market Attractiveness by Product Type, 2024 to 2034
Figure 139: East Asia Market Attractiveness by End User, 2024 to 2034
Figure 140: East Asia Market Attractiveness by Country, 2024 to 2034
Figure 141: Middle East and Africa Market Value (US$ Million) by Disease Indication, 2024 to 2034
Figure 142: Middle East and Africa Market Value (US$ Million) by Product Type, 2024 to 2034
Figure 143: Middle East and Africa Market Value (US$ Million) by End User, 2024 to 2034
Figure 144: Middle East and Africa Market Value (US$ Million) by Country, 2024 to 2034
Figure 145: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 146: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 147: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 148: Middle East and Africa Market Value (US$ Million) Analysis by Disease Indication, 2019 to 2034
Figure 149: Middle East and Africa Market Value Share (%) and BPS Analysis by Disease Indication, 2024 to 2034
Figure 150: Middle East and Africa Market Y-o-Y Growth (%) Projections by Disease Indication, 2024 to 2034
Figure 151: Middle East and Africa Market Value (US$ Million) Analysis by Product Type, 2019 to 2034
Figure 152: Middle East and Africa Market Value Share (%) and BPS Analysis by Product Type, 2024 to 2034
Figure 153: Middle East and Africa Market Y-o-Y Growth (%) Projections by Product Type, 2024 to 2034
Figure 154: Middle East and Africa Market Value (US$ Million) Analysis by End User, 2019 to 2034
Figure 155: Middle East and Africa Market Value Share (%) and BPS Analysis by End User, 2024 to 2034
Figure 156: Middle East and Africa Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034
Figure 157: Middle East and Africa Market Attractiveness by Disease Indication, 2024 to 2034
Figure 158: Middle East and Africa Market Attractiveness by Product Type, 2024 to 2034
Figure 159: Middle East and Africa Market Attractiveness by End User, 2024 to 2034
Figure 160: Middle East and Africa Market Attractiveness by Country, 2024 to 2034
The global antibody market is estimated to be around USD 266.83 billion in 2024.
The global antibody market is to grow at 8.1% during the forecast period.
The global antibody market is predicted to be valued at USD 581.42 billion by 2034.
The global antibody market was valued at USD 131.47 billion in 2019.
The United Kingdom to witness 10.1% CAGR in sales of antibodies through 2034.
Explore Life Science & Biotechnology Insights
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.